Barclays’s Ocugen OCGN Stock Holding History

Barclays’s Portfolio OCGN Stock Details OCGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-6,800	Closed	-$22K	–	5189
2022 Q1	$22K	Buy	+6,800	New	+$23.9K	﹤0.01%	4422

Other funds holding OCGN

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Barclays's OCGN Position: Q1 2026 in Review

Barclays increased its Ocugen (OCGN) stake by 46% in Q1 2026, buying an estimated $126K and bringing the position to 230,618 shares worth $417K. The position accounts for ﹤0.01% of the portfolio, ranked #3291.

Barclays first reported a position in OCGN in Q2 2022 and has held it in 11 quarters since. The position peaked at $2.14M in Q3 2022. 137 funds tracked by Wall St. Rank hold OCGN as of Q1 2026.

Barclays held 230,618 shares of Ocugen worth $417K as of Q1 2026.
Barclays bought 73,118 Ocugen shares in Q1 2026, an estimated $126K.
Ocugen made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3291 holding.
Barclays first reported a position in Ocugen in Q2 2022 and has held it in 11 quarters since.
Barclays's Ocugen position peaked at $2.14M in Q3 2022.
137 funds tracked by Wall St. Rank held Ocugen as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.